# Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

Source: https://onco.cc/trials/nct03974022/  
OnCo record `nct03974022` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Sunvozertinib in non-small-cell lung cancer and small-cell lung cancer, run by Dizal Pharmaceuticals, active and no longer recruiting.

## Summary

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) is a phase 1/2 interventional study registered as NCT03974022 by Dizal Pharmaceuticals, with 315 participants enrolled, started 2019-07-09 and due to reach its primary completion in 2024-07-29. Interventions recorded: Sunvozertinib. Conditions listed: Non-Small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: WU-KONG1
- Tags: ctgov-ingest
- Registry id: NCT03974022
- Phase: 1/2
- Setting: A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR or HER2 Mutation
- Sponsor: Dizal Pharmaceuticals
- Enrolled: 315
- Outcomes: Part B: Objective Response Rate (ORR) According to RECIST 1.1 by an Independent Review Committee (IRC).: Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg 45.9% vs Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg 45.8%

## Sources

- ClinicalTrials.gov NCT03974022: https://clinicaltrials.gov/study/NCT03974022

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [HER2-mutant non-small-cell lung cancer](https://onco.cc/cancers/her2-mutant-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Sunvozertinib](https://onco.cc/drugs/sunvozertinib/)
- companies: [Dizal Pharmaceutical](https://onco.cc/companies/dizal/)
- key papers: [Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)](https://onco.cc/key-papers/paper-nct03974022-j-clin-oncol-2025/)

---
JSON: https://onco.cc/api/v1/entities/nct03974022.json